Objective To investigate the effect of evolocumab combined with levocarnitine after emergency percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI).

Methods A total of 120 STEMI patients were selected and randomly divided into treatment group (60 cases) and control group (60 cases). The control group was given STEMI basic treatment plus levocarnitine, and the treatment group was given evolocumab on the basis of the control group. The therapeutic effectiveness, coronary artery microcirculation B-type natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), coronary arteriole statusThrombolysis in Myocardial Infarction (TIMI) risk score, preprotein converting enzyme subtilysin 9 (PCSK9) and low density lipoprotein cholesterol (LDL-C) and incidence of adverse reactions were compared between the two groups before and after treatment.

Results After treatment, the total effective rate of treatment group was significantly higher than that of control group (P < 0.05). After treatment, BNP level in two groups was significantly lower than before treatment, and the level in the treatment group was significantly lower than that in the control group (P < 0.05); LVEF in the two groups was significantly higher than before treatment, and the treatment group was significantly higher than the control group (P < 0.05). After treatment, the TIMI risk score of the two groups was significantly decreased, and the treatment group was significantly lower than the control group (P < 0.05). The levels of PSCK9 and LDL-C in the two groups were significantly lower than before treatment, and the treatment group was significantly lower than the control group (P < 0.05). After treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion Evolocumab combined with levocarnitine can improve cardiac function and coronary microcirculation in STEMI patients after emergency PCI, and has high safety.